Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Weijie Ma, Barbara M. Gilligan, Jianda Yuan, Tianhong Li

Research output: Contribution to journalReview articlepeer-review

193 Scopus citations

Abstract

Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in some patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other tumor types. About 20 % of advanced NSCLC patients and 30 % of advanced melanoma patients experience tumor responses from checkpoint blockade monotherapy, with better clinical responses seen with the combination of anti-PD-1 and anti-CTLA-4 antibodies. Given the power of these new therapies, it is important to understand the complex and dynamic nature of host immune responses and the regulation of additional molecules in the tumor microenvironment and normal organs in response to the checkpoint blockade therapies. In this era of precision oncology, there remains a largely unmet need to identify the patients who are most likely to benefit from immunotherapy, to optimize the monitoring assays for tumor-specific immune responses, to develop strategies to improve clinical efficacy, and to identify biomarkers so that immune-related adverse events can be avoided. At this time, PD-L1 immunohistochemistry (IHC) staining using 22C3 antibody is the only FDA-approved companion diagnostic for patients with NSCLC-treated pembrolizumab, but more are expected to come to market. We here summarize the current knowledge, clinical efficacy, potential immune biomarkers, and associated assays for immune checkpoint blockade therapies in advanced solid tumors.

Original languageEnglish (US)
Article number47
JournalJournal of Hematology and Oncology
Volume9
Issue number1
DOIs
StatePublished - May 27 2016

Keywords

  • Biomarker
  • Cancer immunotherapy
  • Cytotoxic T cells
  • Immune checkpoint blockade antibodies
  • Immune-related adverse events
  • PD-1
  • PD-L1
  • Precision oncology

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology

Fingerprint Dive into the research topics of 'Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy'. Together they form a unique fingerprint.

Cite this